"A translational research team led by the National University of Singapore NUS has harnessed CURATE.AI a powerful artificial intelligence AI platform to successfully treat a patient with advanced cancer completely halting disease progression. This new development represents a big step forward in personalised medicine.  In this clinical study a patient with metastatic castrationresistant prostate cancer MCRPC was given a novel drug combination consisting of investigational drug ZEN and enzalutamide an approved prostate cancer drug. The research team successfully utilised CURATE.AI to continuously identify the optimal doses of each drug to result in a durable response allowing the patient to resume a completely normal and active lifestyle. Dynamic dosing in cancer therapy is not commonly used. In fact drug dosing changes in oncology are typically performed only to reduce toxicity. CURATE.AI uniquely modifies drug dosing to increase efficacy. Our clinical study has shown that dosing can profoundly affect the efficacy and safety of treatment. A patients clinical profile changes over time. The unique ability for CURATE.AI to rapidly identify the drug doses that result in the best possible treatment outcomes allows for actionable and perpetually optimised personalised medicine explained Professor Dean Ho Director of the Singapore Institute for Neurotechnology SINAPSE at NUS who led the study.  Combating cancer with combination therapy Combination therapy represents a cornerstone in modern cancer treatment. Using this approach multiple drugs are used to attack the processes that support cancer growth. A primary objective when designing combination therapies is to achieve drug synergy where the drugs work together to substantially improve efficacy.  While combination therapy has generally improved treatment outcomes such as overall survival for many cancers it is predominantly given at both fixed as well as high doses.  Prof Ho added Patients respond to chemotherapy differently from one another. Even a single patients response to therapy can vary substantially over the course of treatment. In fact many patients do not respond at all to the drug combination because the dosages which can profoundly impact efficacy are not suitable for them. Therefore while fixed dose combination therapy represents a standard of care it may also serve as a barrier to realising truly optimal and personalised medicine. Harnessing AI to continuously optimise combination therapy dosing To overcome the challenges of conventional combination therapy the NUS team of engineers developed the CURATE.AI platform which uses the patients own clinical data  such as their drug doses and corresponding changes to tumour sizes or levels of cancer biomarkers in the blood  to calibrate his or her unique response to treatment. This calibration is then used to create an individualised CURATE.AI profile or map that identifies the drug doses which enable the best possible treatment outcome at any given point in time.  No two patients profiles are alike and as a patients body and the cancer itself evolve during treatment the CURATE.AI profile evolves as well enabling the clinical and engineering teams to optimise care for the entire duration of treatment an unprecedented advance for combination therapy Prof Ho explained.  In this study which was conducted at the UCLA Institute of Urologic Oncology for a period of over a year a patient with metastatic prostate cancer was given ZEN and enzalutamide. Reducing the level of prostate specific antigen PSA in the patients blood served as the primary biomarker to determine if the patient was responding to treatment. Computed tomography CT imaging of the cancer lesions monitored the extent of disease progression. Initially the doses of ZEN and enzalutamide were adjusted by the clinicians to better manage patientreported quality of life. The patients initial drug doses and PSA levels were then used to construct his personalised CURATE.AI profile. Remarkably CURATE.AI subsequently identified a ZEN dose that was  per cent lower than the patients starting dose of the drug prior to CURATE.AI analysis. Prospective dosage guidance by CURATE.AI resulted in the lowest PSA levels observed for the patient during the course of the study. As treatment progressed slight increases in ZEN dosing resulted in clear decreases in PSA levels also demonstrating its key role in suppressing the metastatic cancer. CT imaging of the patients lesions showed that disease progression was halted as a result of CURATE.AIguided combination therapy of both ZEN and enzalutamide. Patient care guided by CURATE.AI is currently ongoing. Using CURATE.AI to dynamically modify drug doses and successfully treat a metastatic cancer patient represents a landmark breakthrough for the use of AI to truly personalise patient care. This advance is expected to dramatically improve response rates for all combination therapies that are being developed for oncology as well as virtually all other diseases. We can also expect CURATE.AI to markedly reduce the costs of drug development Prof Ho added. Dr Allan Pantuck the lead clinician of the study added With fixed dose therapy patients are often switched to other drugs when they no longer respond to treatment. However CURATE.AI has shown that patients can still respond to the therapies that have seemingly stopped working by continuously identifying the patients optimal dosing parameters.  The implementation of CURATE.AI represents a gamechanging shift in the way that combination therapy can be optimised at the single patient level and we have shown that Nof medicine can be a reality. We are excited that CURATE.AI could ultimately enhance patient accessibility to important new combination therapies saving lives in the process said Prof Ho who is also from the Biomedical Engineering and Pharmacology departments at NUS as well as a member of the Biomedical Institute for Global Health Research and Technology BIGHEART at NUS.  The research was conducted in collaboration with the University of California Los Angeles and Zenith Epigenetics. The findings were published in Advanced Therapeutics on  August .  More clinical trials underway CURATE.AI is applicable to all diseases and all patients and a first generation of the platform was previously validated in the clinic for single drug optimisation in posttransplant immunosuppression. This new study demonstrates that CURATE.AI can optimise multidrug regimens.  Multiple clinical trials using CURATE.AIguided combination therapy for oncology and additional applications such as posttransplant immunosuppression are underway. In addition patient recruitment for additional oncology trials in Singapore has been approved.  The CURATE.AI team expects to broadly deploy the platform for the prevention of transplant rejection adult and paediatric cancers cardiovascular medicine diabetes management infectious diseases and many other applications."